"It takes time to move a technology from bench to bedside. When it comes to DNA testing to determine if breast cancer patients are likely to benefit from tamoxifen, that wait needs to end," stated NFCR President Franklin C. Salisbury, Jr.
"I was impressed from the onset of calling Genelex. From the receptionist to the customer service specialists, everyone was very helpful and reassuring during the whole process. Keep up
the excellent service." - VT, Brooklyn, NY